Deuterium-depleted water, drinking water with part of its heavy hydrogen removed, is used for cancer support, metabolic health and slower aging. Its most encouraging signal is longer survival when cancer patients drink it alongside standard treatment, though nearly all studies come from its seller. Other benefits are weak, mixed or animal-only, and untested in healthy people. Safety appears favorable so far; the larger risk is replacing proven cancer care. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum sodium | 138–142 mmol/L | Detects DDW-linked sodium drop |
| Fasting glucose | 75–90 mg/dL | Tracks glucose response |
| HbA1c | 4.8–5.3% | Three-month glucose average |
| Fasting insulin | 2–6 µIU/mL | Detects insulin shifts seen in trials |
| HDL cholesterol | 55–85 mg/dL | Tracks reported HDL rise |
| Complete blood count | Within laboratory reference range | Blood counts rose in the 90-day study |
| Body deuterium (saliva, urine or serum) | No established target; change from own baseline | Confirms real depletion |
| eGFR and creatinine | Above 90 mL/min/1.73 m² | Kidney handling of water and sodium |
| Disease markers (e.g., PSA) | No universal target; change from own baseline | Tracks cancer activity; only for people with cancer |
Cadence: Baseline before starting; at 4–6 weeks, at 3 months, then every 3–6 months while use continues, plus 4–6 weeks after stopping